# Sermorelin Side Effects in the Research Literature > Sermorelin side effects documented in clinical trials: injection-site reactions, arthralgia, peripheral edema, and myalgia. Long-term data beyond 12 months is limited. ## Sermorelin safety profile in clinical studies Clinical trials characterize sermorelin as generally well-tolerated; serious adverse events are rare; injection-site reactions and transient headache are the most commonly reported findings [14]. The Biomolecules 2024 review of FDA-approved and studied peptide analogs compiled the adverse-event profile from clinical studies: documented adverse effects include arthralgia, erythema at injection site, pruritus at injection site, pain in extremities, peripheral edema, and myalgia [14]. The Vitiello 2001 aging study, which used once-nightly subcutaneous sermorelin at approximately 14 mcg/kg for 5-6 months, reported that once-nightly doses were well tolerated with very uncommon peripheral edema or arthralgias [4]. The Koutkia 2004 JAMA RCT (1 mg subcutaneous twice daily for 12 weeks) characterized the therapy as well tolerated in 31 HIV-infected men [10]. The Geref International Study Group multicenter pediatric trial (Thorner 1996) reported no adverse metabolic changes, normal fasting glucose, and appropriate IGF-I levels across 110 children followed for up to 12 months [2]. ## What are the downsides of Sermorelin? Reported adverse effects in clinical studies include injection-site reactions (erythema, pruritus, pain), headache, flushing, dizziness, and nausea; fluid retention (peripheral edema) and joint discomfort (arthralgia) have been noted at higher doses or in susceptible individuals [14]. Subcutaneous bioavailability is less than 4%, which means injection is the only route with documented efficacy — no oral formulation has been shown to work in clinical trials [14]. The Vitiello 2001 aging study noted a small but statistically significant worsening of subjective sleep quality scores (PSQI) despite objective IGF-1 elevation, which the authors described as a finding of unclear mechanism [4]. ## Long-term safety data for Sermorelin Long-term safety data in humans is limited; the longest reported tolerability data comes from studies of 5-6 months (Vitiello 2001) and 12 months (Thorner 1996 pediatric trial, Ogilvy-Stuart 1997). Extended placebo-controlled studies beyond 6 months in healthy aging adults have not been published since the 2008 Geref market withdrawal [4][2][16]. The Walker 2006 review in Clinical Interventions in Aging noted the theoretical safety advantage of preserved pituitary feedback: because somatostatin and IGF-1 continue to regulate GH output under sermorelin administration, the risk of supraphysiological GH/IGF-1 exposure is substantially reduced compared to exogenous GH [5]. ## Drug interactions and Sermorelin co-administration Glucocorticoids may blunt the GH response to sermorelin. The mechanistic basis: glucocorticoids suppress GH secretion by increasing hypothalamic somatostatin tone via enhanced beta-adrenergic responsiveness in somatostatin neurons [13]. In the Sigalos 2017 study, concurrent aromatase inhibitor or tamoxifen use blunted IGF-1 response to the combination GH secretagogue protocol that included sermorelin [9]. ## Sermorelin contraindications in the literature Studies exclude subjects with active malignancy, hypothyroidism, or hypersensitivity to GHRH analogs [2][14]. Hypothyroidism is specifically relevant: thyroid hormone deficiency blunts pituitary responsiveness to GHRH, meaning GH response to sermorelin may be absent or attenuated in hypothyroid subjects. Athletes governed by the WADA code face a legal prohibition: sermorelin is classified S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), prohibited in-competition and out-of-competition. A Therapeutic Use Exemption (TUE) would be required for any WADA-governed athlete with a legitimate medical need [1]. --- A bright, plain-spoken digest of the peer-reviewed Sermorelin record — GHRH(1-29) literature sorted and cited, no clinic behind the name.